#1 Clinical Trials Search in Europe

Hct116-A

This article discusses the clinical trials of STC-1010, an innovative immunotherapy drug being tested for patients with advanced or metastatic colorectal cancer. The BreAK CRC trial aims to evaluate the safety, efficacy, and optimal dosing of STC-1010 when combined with standard-of-care treatments. This study offers hope for patients with limited treatment options and may potentially improve outcomes for those battling this challenging form of cancer.

Table of Contents

What is STC-1010?

STC-1010 is a new immunotherapy drug being developed to treat advanced or metastatic colorectal cancer. It’s currently being studied in a clinical trial called the BreAK CRC trial[1]. STC-1010 is also known as “Stimulated Tumor Cells-1010,” which gives us a clue about how it works.

How Does STC-1010 Work?

STC-1010 is a type of treatment called cell therapy. It’s made up of six different components, all derived from colorectal cancer cells:

  • HCT116-A
  • HCT116-B
  • HT-29-A
  • HT-29-B
  • LOVO-A
  • LOVO-B
These components are designed to stimulate your immune system to fight against colorectal cancer cells in your body[1].

STC-1010 is given as an intradermal injection, which means it’s injected just under the skin. This method helps to activate your immune system effectively.

Who Might Benefit from STC-1010?

STC-1010 is being studied for patients with:

  • Unresectable locally advanced colorectal cancer: This means cancer that has spread locally but can’t be completely removed with surgery.
  • Metastatic colorectal cancer: This is cancer that has spread to other parts of the body.
The trial is looking at two main groups of patients:
  1. Those with MSS (microsatellite stable) tumors who haven’t had treatment before.
  2. Those with MSI-H (microsatellite instability-high) tumors, including Lynch syndrome, who have already tried immunotherapy but it didn’t work[1].

The BreAK CRC Clinical Trial

The BreAK CRC trial is studying STC-1010 in combination with other cancer treatments. It has two main parts:

  1. Phase I: This part is testing different doses of STC-1010 to find the safest and most effective dose.
  2. Phase IIA: This part is looking at how well STC-1010 works in larger groups of patients[1].

In both phases, STC-1010 is given along with standard chemotherapy drugs (like FOLFOX) and other targeted therapies (like bevacizumab). The treatment is given in two stages:

  1. Induction treatment: Up to 8 cycles of more intense treatment.
  2. Maintenance treatment: Less intense treatment that continues for a longer time[1].

Eligibility for the Trial

To join the trial, patients need to meet certain criteria. Some key points include:

  • Age 18-75 years
  • Confirmed diagnosis of advanced or metastatic colorectal cancer
  • Good overall health status
  • No active autoimmune diseases
  • No recent major surgery or radiation therapy
There are many other specific criteria that your doctor would need to check[1].

Potential Benefits and Risks

The main goals of the STC-1010 treatment are to:

  • Slow down or stop the growth of cancer
  • Improve survival rates, especially for patients who haven’t responded to other treatments
  • Provide a new option for patients with advanced colorectal cancer

However, as with any new treatment, there may be risks and side effects. The trial is carefully monitoring patients for any adverse events. Some potential risks could include immune-related side effects, as STC-1010 works by stimulating the immune system[1].

It’s important to remember that STC-1010 is still in the testing phase. More research is needed to fully understand its effectiveness and safety. If you’re interested in this treatment, talk to your oncologist about whether you might be eligible for the clinical trial.

Aspect Details
Drug Name STC-1010 (Stimulated Tumor Cells-1010)
Trial Name BreAK CRC (BreAK for Brenus Anti-cancer)
Trial Phase Phase I/IIA
Target Condition Unresectable locally advanced or metastatic colorectal cancer
Main Objectives Evaluate safety, determine optimal dose, assess clinical efficacy
Treatment Combination STC-1010 with standard-of-care therapy (e.g., mFOLFOX6 + bevacizumab)
Patient Groups MSS/pMMR and MSI-H/dMMR colorectal cancer patients
Primary Endpoint Phase I: Safety profile; Phase IIA: Progression-free survival at 12 months

FAQ

  • What is STC-1010 and how does it work? STC-1010 is an immunotherapy drug being tested for advanced colorectal cancer. It works by stimulating the body's immune system to fight cancer cells. The drug is administered along with standard chemotherapy and other treatments to potentially enhance their effectiveness.
  • Who is eligible for the BreAK CRC trial? The trial is primarily for adults aged 18-75 with unresectable locally advanced or metastatic colorectal cancer. Participants must meet specific health criteria, including adequate organ function and a life expectancy of over 3 months. The study includes different arms for patients with specific tumor characteristics.
  • What are the phases of the BreAK CRC trial? The trial consists of two main phases. Phase I focuses on determining the safety and optimal dose of STC-1010. Phase IIA aims to evaluate the clinical effectiveness of STC-1010 when combined with standard treatments in different patient groups, including those with MSS (microsatellite stable) and MSI-H (microsatellite instability-high) tumors.
  • What treatments are given alongside STC-1010 in the trial? Participants receive STC-1010 along with standard-of-care treatments. This typically includes chemotherapy regimens like mFOLFOX6 (a combination of chemotherapy drugs) and bevacizumab (a targeted therapy). The exact combination and duration may vary depending on the trial phase and patient group.
  • What are the potential benefits and risks of participating in this trial? Potential benefits include access to a new immunotherapy that may improve cancer treatment outcomes. However, as with any clinical trial, there are risks of side effects and the possibility that the treatment may not be effective. The trial closely monitors participants for any adverse events and adjusts treatment as necessary to ensure patient safety.

Ongoing Clinical Trials on Hct116-A

  • Study on STC-1010 and Drug Combination for Patients with Advanced or Metastatic Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

Glossary

  • Immunotherapy: A type of cancer treatment that helps your immune system fight cancer cells.
  • Metastatic: Cancer that has spread from where it started to other parts of the body.
  • Unresectable: Unable to be removed completely through surgery.
  • Standard of Care (SOC): The best known treatment currently used for a specific condition.
  • mFOLFOX6: A combination chemotherapy regimen used to treat colorectal cancer.
  • Bevacizumab: A targeted therapy drug that helps prevent the growth of new blood vessels that feed tumors.
  • Microsatellite Stable (MSS): A type of colorectal cancer that doesn't have errors in DNA repair genes.
  • Microsatellite Instability-High (MSI-H): A type of colorectal cancer with many errors in DNA repair genes, often more responsive to immunotherapy.
  • BRAF: A gene that, when mutated, can contribute to cancer growth.
  • Dose-Escalation: A method in clinical trials where the dose of a drug is gradually increased to find the optimal safe dose.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. http://clinicaltrials.eu/trial/study-on-stc-1010-and-drug-combination-for-patients-with-advanced-or-metastatic-colorectal-cancer/